XTL Biopharmaceuticals Statistics Share Statistics XTL Biopharmaceuticals has 5.45M
shares outstanding. The number of shares has increased by 10.66%
in one year.
Shares Outstanding 5.45M Shares Change (YoY) 10.66% Shares Change (QoQ) 0% Owned by Institutions (%) 0.05% Shares Floating 5.32M Failed to Deliver (FTD) Shares 5,796 FTD / Avg. Volume 15.51%
Short Selling Information The latest short interest is 25.05K, so 0.28% of the outstanding
shares have been sold short.
Short Interest 25.05K Short % of Shares Out 0.28% Short % of Float 0.37% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -13.3 and the forward
PE ratio is null.
XTL Biopharmaceuticals's PEG ratio is
0.
PE Ratio -13.3 Forward PE n/a PS Ratio 30.29 Forward PS n/a PB Ratio 2.51 P/FCF Ratio -8.17 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for XTL Biopharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.61,
with a Debt / Equity ratio of 0.03.
Current Ratio 0.61 Quick Ratio 0.61 Debt / Equity 0.03 Debt / EBITDA -0.15 Debt / FCF -0.08 Interest Coverage -25.26
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $45.1K Profits Per Employee $-102.7K Employee Count 10 Asset Turnover 0.05 Inventory Turnover n/a
Taxes Income Tax -130K Effective Tax Rate 11.24%
Stock Price Statistics The stock price has increased by -40.96% in the
last 52 weeks. The beta is 0.97, so XTL Biopharmaceuticals's
price volatility has been higher than the market average.
Beta 0.97 52-Week Price Change -40.96% 50-Day Moving Average 1.38 200-Day Moving Average 1.5 Relative Strength Index (RSI) 44.17 Average Volume (20 Days) 37,377
Income Statement In the last 12 months, XTL Biopharmaceuticals had revenue of 451K
and earned -1.03M
in profits. Earnings per share was -0.15.
Revenue 451K Gross Profit 3K Operating Income -2.17M Net Income -1.03M EBITDA -930K EBIT -1.13M Earnings Per Share (EPS) -0.15
Full Income Statement Balance Sheet The company has 371K in cash and 138K in
debt, giving a net cash position of 233K.
Cash & Cash Equivalents 371K Total Debt 138K Net Cash 233K Retained Earnings -159.01M Total Assets 8.55M Working Capital -867K
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -1.62M
and capital expenditures -54K, giving a free cash flow of -1.67M.
Operating Cash Flow -1.62M Capital Expenditures -54K Free Cash Flow -1.67M FCF Per Share -0.25
Full Cash Flow Statement Margins Gross margin is 0.67%, with operating and profit margins of -481.6% and -227.72%.
Gross Margin 0.67% Operating Margin -481.6% Pretax Margin -256.54% Profit Margin -227.72% EBITDA Margin -206.21% EBIT Margin -481.6% FCF Margin -370.73%
Dividends & Yields XTLB does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for XTLB.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Feb 10, 2017. It was a
backward
split with a ratio of 1:5.
Last Split Date Feb 10, 2017 Split Type backward Split Ratio 1:5
Scores Altman Z-Score -25.39 Piotroski F-Score 2
